Surgical management of pituitary metastases

Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216. doi: 10.1530/eje.1.02326

Quaresma M, Coleman MP, Rachet B (2014) 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet. doi: 10.1016/S0140-6736(14)61396-9

He W, Chen F, Dalm B, Kirby PA, Greenlee JD (2014) Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis. Pituitary. doi: 10.1007/s11102-014-0552-2

Fassett DR, Couldwell WT (2004) Metastases to the pituitary gland. Neurosurg Focus 16(4):E8

Morita A, Meyer FB, Laws ER Jr (1998) Symptomatic pituitary metastases. J Neurosurg 89(1):69–73. doi: 10.3171/jns.1998.89.1.0069

Buchfelder M, Schlaffer S (2014) Imaging of pituitary pathology. Handbook Clin Neurol 124:151–166. doi: 10.1016/B978-0-444-59602-4.00011-3

Kovacs K (1973) Metastatic cancer of the pituitary gland. Oncology 27(6):533–542

Branch CL Jr, Laws ER Jr (1987) Metastatic tumors of the sella turcica masquerading as primary pituitary tumors. J Clin Endocrinol Metab 65(3):469–474. doi: 10.1210/jcem-65-3-469

McCormick PC, Post KD, Kandji AD, Hays AP (1989) Metastatic carcinoma to the pituitary gland. Br J Neurosurg 3(1):71–79

Flitsch J, Bernreuther C, Hagel C, Ludecke DK (2008) Hypophysectomy for prostate cancer: A revival of old knowledge? J Neurosurg 109(4):760–764. doi: 10.3171/JNS/2008/109/10/0760

Abrams HL, Spiro R, Goldstein N (1950) Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 3(1):74–85

Marin F, Kovacs KT, Scheithauer BW, Young WF Jr (1992) The pituitary gland in patients with breast carcinoma: a histologic and immunocytochemical study of 125 cases. Mayo Clin Proc 67(10):949–956

Houck WA, Olson KB, Horton J (1970) Clinical features of tumor metastasis to the pituitary. Cancer 26(3):656–659

Kimmel DW, O’Neill BP (1983) Systemic cancer presenting as diabetes insipidus. Clinical and radiographic features of 11 patients with a review of metastatic-induced diabetes insipidus. Cancer 52(12):2355–2358

Oi S, Ciric I, Mayer TK (1978) Metastatic breast carcinoma in the pituitary gland. Brain Nerve 30(1):69–73

Komninos J, Vlassopoulou V, Protopapa D, Korfias S, Kontogeorgos G, Sakas DE, Thalassinos NC (2004) Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 89(2):574–580. doi: 10.1210/jc.2003-030395

Sioutos P, Yen V, Arbit E (1996) Pituitary gland metastases. Ann Surg Oncol 3(1):94–99

Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA (1981) A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305(10):545–551. doi: 10.1056/NEJM198109033051003

Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24(12):1868–1876. doi: 10.1200/JCO.2005.04.7423

Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pierart M, Mauer ME, Collette L, Group, E.R.O., Genito-Urinary Tract Cancer, G. (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527. doi: 10.1056/NEJMoa0810095

Early Breast Cancer Trialists’ Collaborative, G., Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. doi: 10.1016/S0140-6736(11)60993-8

Schiavon G, Smith IE (2014) Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res 16(2):206

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479. doi: 10.1016/j.eururo.2013.11.002

Kluth LA, Shariat SF, Kratzik C, Tagawa S, Sonpavde G, Rieken M, Scherr DS, Pummer K (2014) The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol 32(3):669–676. doi: 10.1007/s00345-013-1157-5

Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132(7):566–577

Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T (2001) Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis 4(4):196–203. doi: 10.1038/sj.pcan.4500531

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, Investigators P (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433. doi: 10.1056/NEJMoa1405095